Biomarkers /
PR Expression
Back to Biomarkers List
Associated Diseases
Overview
Biomarker-Directed Therapies
PR Expression is a predictive biomarker for use of fulvestrant, aromatase inhibitor, everolimus, exemestane, trastuzumab, anastrozole, letrozole, abemaciclib, endocrine therapy, tamoxifen, alpelisib, lapatinib, palbociclib, ribociclib, ado-trastuzumab emtansine, ivosidenib, pertuzumab, and toremifene in patients.
Of the therapies with PR Expression as a predictive biomarker, 13 are FDA-approved and 17 have NCCN guidelines in at least one clinical setting.
Breast carcinoma and breast invasive lobular carcinoma have the most therapies targeted against PR Expression or its related pathways [5].
Abemaciclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. |
Anastrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for locally advanced or metastatic breast cancer as first-line treatment or after progression on tamoxifen. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NICE, SMC) | |
| Note: Please note that NICE guidance stipulates estrogen receptor (ER) expression as the criterion for primary adjuvant therapy with anastrozole, not progesterone receptor (PR). |
Everolimus +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for metastatic disease. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, and for HR-positive advanced disease with progression following endocrine therapy. |
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (BNF) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Ivosidenib +
Breast Invasive Lobular Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Sensitive |
| Clinical Setting(s): Metastatic (BNF) |
Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive breast cancer, as adjuvant treatment, and for advanced breast cancer as first-line treatment or after progression following antiestrogen therapy. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Neoadjuvant (BNF) |
Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (FDA, NCCN), Metastatic (FDA, NCCN) | |
| Note: Indicated for HR+ breast cancer, both as adjuvant treatment and in the metastatic setting. |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NICE) |
Toremifene +
Breast Carcinoma -
Abemaciclib + Aromatase Inhibitor +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer. |
Abemaciclib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Ado-Trastuzumab Emtansine + Endocrine Therapy +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer. |
Alpelisib + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen. |
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: PIK3CA E545Q, PIK3CA Q546K, PIK3CA Q546P, PIK3CA E365K, PIK3CA E453K, PIK3CA G1049R, PIK3CA G106V, PIK3CA G118D, PIK3CA K111E, PIK3CA K111N, PIK3CA M1043I, PIK3CA M1043V, PIK3CA N345K, PIK3CA P447_L455del, PIK3CA P539R, PIK3CA R108H, PIK3CA R88Q, PIK3CA R93W, PIK3CA T1025A, PIK3CA V344G, PIK3CA V344M Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative, PIK3CA-mutated, recurrent or metastatic breast cancer. |
Anastrozole + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as first line therapy. |
Aromatase Inhibitor + Lapatinib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved with letrozole as the aromatase inhibitor for postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. NCCN recommended for any aromatase inhibitor. |
Aromatase Inhibitor + Lapatinib + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positve/HER2-positive recurrent or metastastic breast cancer. |
Aromatase Inhibitor + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: FDA approved for HR-positive, HER2-negative advanced or metastatic breast cancer as initial endocrine-based therapy in postmenopausal women or in men. |
Aromatase Inhibitor + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for pre/perimenopausal or postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine-based therapy. |
Aromatase Inhibitor + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
|
Biomarker Criteria:
Sample must match all of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (SMC) |
Endocrine Therapy + Pertuzumab + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN) | |
| Note: Recommended for adjuvant treatment of HR-positive, HER2-positive breast cancer, with or without chemotherapy. |
Endocrine Therapy + Trastuzumab +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match one or more of the following:
|
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Adjuvant (NCCN), Metastatic (NCCN) | |
| Note: Recommend for HR-positive/HER2-positive breast cancer, with fulvestrant, tamoxifen, or aromatase inhibitor metastastic disease, or with tamoxifen or aromatase inhibitor for adjuvant treatment. |
Everolimus + Exemestane +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with advanced HR+, HER2- breast cancer after failure of treatment with letrozole or anastrozole. |
Everolimus + Fulvestrant +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as subsequent line therapy. |
Everolimus + Tamoxifen +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastatic breast cancer as subsequent line therapy. |
Fulvestrant + Letrozole +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (NCCN) | |
| Note: Recommended for HR-positive, HER2-negative recurrent or metastastic breast cancer as first line therapy. |
Fulvestrant + Palbociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match all of the following: Sample must match all of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. |
Fulvestrant + Ribociclib +
Breast Carcinoma -
|
Biomarker Criteria:
Sample must match all of the following:
Sample must match one or more of the following: Sample must match one or more of the following: |
Predicted Response: Primary Sensitivity |
| Clinical Setting(s): Metastatic (FDA, NCCN) | |
| Note: Indicated for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, as initial endocrine based therapy, or following disease progression on endocrine therapy. |
Clinical Trials
PR Expression serves as an inclusion eligibility criterion in 330 clinical trials, of which 251 are open and 79 are closed. Of the trials that contain PR Expression as an inclusion criterion, 6 are early phase 1 (4 open), 65 are phase 1 (53 open), 34 are phase 1/phase 2 (27 open), 145 are phase 2 (104 open), 4 are phase 2/phase 3 (3 open), 53 are phase 3 (42 open), 5 are phase 4 (2 open), and 18 are no phase specified (16 open).
Trials with PR Expression in the inclusion eligibility criteria most commonly target breast carcinoma, invasive breast carcinoma, breast adenocarcinoma, breast invasive ductal carcinoma, and ductal carcinoma in situ [5].
Fulvestrant, letrozole, palbociclib, placebo, and abemaciclib are the most frequent therapies in trials with PR Expression as an inclusion criteria [5].
Significance of PR Expression in Diseases
Breast Carcinoma +
PR Expression is an inclusion criterion in 279 clinical trials for breast carcinoma, of which 205 are open and 74 are closed. Of the trials that contain PR Expression and breast carcinoma as inclusion criteria, 5 are early phase 1 (3 open), 60 are phase 1 (49 open), 30 are phase 1/phase 2 (24 open), 122 are phase 2 (82 open), 4 are phase 2/phase 3 (3 open), 42 are phase 3 (32 open), 5 are phase 4 (2 open), and 11 are no phase specified (10 open) [5].
Letrozole, anastrozole, fulvestrant, exemestane, everolimus, tamoxifen, alpelisib, aromatase inhibitor, trastuzumab, abemaciclib, ribociclib, palbociclib, endocrine therapy, pertuzumab, lapatinib, ado-trastuzumab emtansine, and toremifene have evidence of efficacy in patients with PR Expression in breast carcinoma [5].
Breast Invasive Lobular Carcinoma +
PR Expression is an inclusion criterion in 3 clinical trials for breast invasive lobular carcinoma, of which 3 are open and 0 are closed. Of the trials that contain PR Expression and breast invasive lobular carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].
Ivosidenib has evidence of efficacy in patients with PR Expression in breast invasive lobular carcinoma [5].
Malignant Solid Tumor +
PR Expression is an inclusion criterion in 26 clinical trials for malignant solid tumor, of which 22 are open and 4 are closed. Of the trials that contain PR Expression and malignant solid tumor as inclusion criteria, 19 are phase 1 (16 open), 4 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].
Invasive Breast Carcinoma +
PR Expression is an inclusion criterion in 19 clinical trials for invasive breast carcinoma, of which 18 are open and 1 is closed. Of the trials that contain PR Expression and invasive breast carcinoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (1 open), 9 are phase 2 (9 open), 5 are phase 3 (5 open), and 1 is no phase specified (1 open) [5].
Breast Adenocarcinoma +
PR Expression is an inclusion criterion in 16 clinical trials for breast adenocarcinoma, of which 15 are open and 1 is closed. Of the trials that contain PR Expression and breast adenocarcinoma as inclusion criteria, 1 is early phase 1 (1 open), 2 are phase 1 (2 open), 4 are phase 2 (4 open), 6 are phase 3 (5 open), and 3 are no phase specified (3 open) [5].
Ovarian Carcinoma +
PR Expression is an inclusion criterion in 14 clinical trials for ovarian carcinoma, of which 11 are open and 3 are closed. Of the trials that contain PR Expression and ovarian carcinoma as inclusion criteria, 8 are phase 1 (6 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].
Non-Small Cell Lung Carcinoma +
PR Expression is an inclusion criterion in 9 clinical trials for non-small cell lung carcinoma, of which 8 are open and 1 is closed. Of the trials that contain PR Expression and non-small cell lung carcinoma as inclusion criteria, 6 are phase 1 (6 open) and 3 are phase 2 (2 open) [5].
Fallopian Tube Carcinoma +
PR Expression is an inclusion criterion in 8 clinical trials for fallopian tube carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PR Expression and fallopian tube carcinoma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].
Primary Peritoneal Carcinoma +
PR Expression is an inclusion criterion in 8 clinical trials for primary peritoneal carcinoma, of which 6 are open and 2 are closed. Of the trials that contain PR Expression and primary peritoneal carcinoma as inclusion criteria, 5 are phase 1 (4 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].
Colorectal Carcinoma +
PR Expression is an inclusion criterion in 7 clinical trials for colorectal carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PR Expression and colorectal carcinoma as inclusion criteria, 6 are phase 1 (6 open) and 1 is phase 1/phase 2 (1 open) [5].
Endometrial Carcinoma +
PR Expression is an inclusion criterion in 7 clinical trials for endometrial carcinoma, of which 7 are open and 0 are closed. Of the trials that contain PR Expression and endometrial carcinoma as inclusion criteria, 4 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].
Prostate Carcinoma +
PR Expression is an inclusion criterion in 6 clinical trials for prostate carcinoma, of which 6 are open and 0 are closed. Of the trials that contain PR Expression and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].
Small Cell Lung Carcinoma +
PR Expression is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PR Expression and small cell lung carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 2 are phase 1/phase 2 (1 open) [5].
Urothelial Carcinoma +
PR Expression is an inclusion criterion in 5 clinical trials for urothelial carcinoma, of which 5 are open and 0 are closed. Of the trials that contain PR Expression and urothelial carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 3 are phase 2 (3 open) [5].
Cervical Carcinoma +
PR Expression is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 4 are open and 0 are closed. Of the trials that contain PR Expression and cervical carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 2 (1 open) [5].
Ductal Carcinoma In Situ +
PR Expression is an inclusion criterion in 4 clinical trials for ductal carcinoma in situ, of which 3 are open and 1 is closed. Of the trials that contain PR Expression and ductal carcinoma in situ as inclusion criteria, 2 are phase 2 (1 open) and 2 are no phase specified (2 open) [5].
Endometrial Endometrioid Adenocarcinoma +
PR Expression is an inclusion criterion in 4 clinical trials for endometrial endometrioid adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain PR Expression and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [5].
Melanoma +
PR Expression is an inclusion criterion in 4 clinical trials for melanoma, of which 3 are open and 1 is closed. Of the trials that contain PR Expression and melanoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [5].
Non-Hodgkin Lymphoma +
PR Expression is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 4 are open and 0 are closed. Of the trials that contain PR Expression and non-hodgkin lymphoma as inclusion criteria, 4 are phase 1 (4 open) [5].
Adenocarcinoma Of The Gastroesophageal Junction +
PR Expression is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain PR Expression and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].
Breast Invasive Ductal Carcinoma +
PR Expression is an inclusion criterion in 3 clinical trials for breast invasive ductal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR Expression and breast invasive ductal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is no phase specified (0 open) [5].
Endometrial Mixed Adenocarcinoma +
PR Expression is an inclusion criterion in 3 clinical trials for endometrial mixed adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR Expression and endometrial mixed adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].
Prostate Adenocarcinoma +
PR Expression is an inclusion criterion in 3 clinical trials for prostate adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain PR Expression and prostate adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [5].
Biliary Tract Carcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for biliary tract carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and biliary tract carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].
Cancer +
PR Expression is an inclusion criterion in 2 clinical trials for cancer, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and cancer as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Endometrial Clear Cell Adenocarcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for endometrial clear cell adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and endometrial clear cell adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Endometrial Serous Adenocarcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for endometrial serous adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and endometrial serous adenocarcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Endometrial Undifferentiated Carcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for endometrial undifferentiated carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and endometrial undifferentiated carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].
Gastric Adenocarcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and gastric adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Gastric Carcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].
Glioblastoma +
PR Expression is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Head And Neck Squamous Cell Carcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Hepatocellular Carcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Lung Adenocarcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and lung adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Medullary Breast Carcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for medullary breast carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and medullary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].
Pancreatic Adenocarcinoma +
PR Expression is an inclusion criterion in 2 clinical trials for pancreatic adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain PR Expression and pancreatic adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) [5].
Adenoid Cystic Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for adenoid cystic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and adenoid cystic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Anaplastic Astrocytoma +
PR Expression is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Bladder Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Breast Lobular Carcinoma In Situ +
PR Expression is an inclusion criterion in 1 clinical trial for breast lobular carcinoma in situ, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and breast lobular carcinoma in situ as inclusion criteria, 1 is no phase specified (1 open) [5].
Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Clear Cell Renal Cell Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Colon Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for colon carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and colon carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Desmoid-Type Fibromatosis +
PR Expression is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1 (1 open) [5].
Endometrial Adenocarcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and endometrial adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Dedifferentiated Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for endometrial dedifferentiated carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and endometrial dedifferentiated carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Mucinous Adenocarcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for endometrial mucinous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and endometrial mucinous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Squamous Cell Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for endometrial squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and endometrial squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrial Transitional Cell Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for endometrial transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and endometrial transitional cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Endometrioid Adenocarcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Esophageal Adenocarcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Esophageal Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Esophageal Squamous Cell Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Gastrointestinal Neuroendocrine Tumors +
PR Expression is an inclusion criterion in 1 clinical trial for gastrointestinal neuroendocrine tumors, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and gastrointestinal neuroendocrine tumors as inclusion criteria, 1 is phase 2 (1 open) [5].
Hypopharyngeal Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for hypopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and hypopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Inflammatory Breast Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for inflammatory breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and inflammatory breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Invasive Papillary Breast Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for invasive papillary breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and invasive papillary breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Laryngeal Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for laryngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and laryngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Liposarcoma +
PR Expression is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and liposarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Low Grade Ovarian Serous Adenocarcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lung Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Lung Neuroendocrine Neoplasm +
PR Expression is an inclusion criterion in 1 clinical trial for lung neuroendocrine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and lung neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Lymphoma +
PR Expression is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Malignant Ovarian Serous Tumor +
PR Expression is an inclusion criterion in 1 clinical trial for malignant ovarian serous tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and malignant ovarian serous tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Malignant Uterine Neoplasm +
PR Expression is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].
Mixed Lobular And Ductal Breast Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for mixed lobular and ductal breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and mixed lobular and ductal breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Mucinous Breast Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for mucinous breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and mucinous breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Neuroendocrine Tumor +
PR Expression is an inclusion criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Non-Clear Cell Renal Cell Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Non-Squamous Non-Small Cell Lung Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for non-squamous non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and non-squamous non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Oral Cavity Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Oropharyngeal Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Endometrioid Adenocarcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Epithelial Tumor +
PR Expression is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Ovarian Granulosa Cell Tumor +
PR Expression is an inclusion criterion in 1 clinical trial for ovarian granulosa cell tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and ovarian granulosa cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Pancreatic Neuroendocrine Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and pancreatic neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Pancreatic Neuroendocrine Neoplasm +
PR Expression is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine neoplasm, of which 0 are open and 1 is closed. Of the trial that contains PR Expression and pancreatic neuroendocrine neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].
Pancreatic Neuroendocrine Tumor +
PR Expression is an inclusion criterion in 1 clinical trial for pancreatic neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and pancreatic neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].
Peritoneal Mesothelioma +
PR Expression is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].
Primary Peritoneal Serous Adenocarcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for primary peritoneal serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and primary peritoneal serous adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Prostate Undifferentiated Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for prostate undifferentiated carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR Expression and prostate undifferentiated carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].
Renal Cell Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PR Expression and renal cell carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].
Sarcoma +
PR Expression is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].
Squamous Cell Lung Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Transitional Cell Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for transitional cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and transitional cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Tubular Breast Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for tubular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and tubular breast carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Ureter Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for ureter carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and ureter carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].
Uterine Sarcoma +
PR Expression is an inclusion criterion in 1 clinical trial for uterine sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and uterine sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Vaginal Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and vaginal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
Vulvar Carcinoma +
PR Expression is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PR Expression and vulvar carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
5. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.
